Ackman supports Allergan's $66 billion sale to Actavis
Reuters
Published Nov 18, 2014 01:44PM ET
Ackman supports Allergan's $66 billion sale to Actavis
(Reuters) - Activist investor William Ackman said on Tuesday he supports the $66 billion deal in which Actavis PLC will buy Allergan Inc and will withdraw his request for an Allergan special shareholder meeting.
Ackman, who had been fighting alongside Valeant Pharmaceuticals International Inc for control of Allergan, had called for the Allergan meeting to vote out board members and force the company to the table to consider their joint offer. The meeting is scheduled for Dec. 18.
"We congratulate Actavis and Allergan on their announced transaction. As a result of the deal, we are withdrawing our special meeting request," Ackman said in an e-mailed statement.
Ackman's comments come after Actavis said on Monday it would pay $219 per share for Allergan, billions more than Valeant was willing to pay. Ackman, who owns nearly 10 percent of Allergan, had paper gains of more than $2.3 billion based on that price.
CNBC reported earlier that Ackman will meet with executives from Actavis later this week.
(Reporting by Caroline Humer; editing by Gunna Dickson)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.